KINIKSA PHARMACEUTICALS INTE (KNSA) Fundamental Analysis & Valuation

NASDAQ:KNSA • GB00BRXB0C07

Current stock price

45.78 USD
-0.29 (-0.63%)
At close:
45.78 USD
0 (0%)
After Hours:

This KNSA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. KNSA Profitability Analysis

1.1 Basic Checks

  • KNSA had positive earnings in the past year.
  • KNSA had a positive operating cash flow in the past year.
  • In multiple years KNSA reported negative net income over the last 5 years.
  • Of the past 5 years KNSA 4 years had a positive operating cash flow.
KNSA Yearly Net Income VS EBIT VS OCF VS FCFKNSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • The Return On Assets of KNSA (7.73%) is better than 92.68% of its industry peers.
  • Looking at the Return On Equity, with a value of 10.40%, KNSA belongs to the top of the industry, outperforming 93.06% of the companies in the same industry.
  • KNSA's Return On Invested Capital of 8.21% is amongst the best of the industry. KNSA outperforms 92.87% of its industry peers.
Industry RankSector Rank
ROA 7.73%
ROE 10.4%
ROIC 8.21%
ROA(3y)0.99%
ROA(5y)-5%
ROE(3y)1.25%
ROE(5y)-7.06%
ROIC(3y)N/A
ROIC(5y)N/A
KNSA Yearly ROA, ROE, ROICKNSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200

1.3 Margins

  • Looking at the Profit Margin, with a value of 8.71%, KNSA belongs to the top of the industry, outperforming 90.17% of the companies in the same industry.
  • KNSA's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 11.40%, KNSA belongs to the top of the industry, outperforming 91.33% of the companies in the same industry.
  • KNSA's Operating Margin has improved in the last couple of years.
  • The Gross Margin of KNSA (88.54%) is better than 90.17% of its industry peers.
  • In the last couple of years the Gross Margin of KNSA has remained more or less at the same level.
Industry RankSector Rank
OM 11.4%
PM (TTM) 8.71%
GM 88.54%
OM growth 3Y36.93%
OM growth 5YN/A
PM growth 3Y-52.89%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5YN/A
KNSA Yearly Profit, Operating, Gross MarginsKNSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. KNSA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), KNSA is destroying value.
  • KNSA has more shares outstanding than it did 1 year ago.
  • KNSA has more shares outstanding than it did 5 years ago.
  • KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KNSA Yearly Shares OutstandingKNSA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
KNSA Yearly Total Debt VS Total AssetsKNSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 11.78 indicates that KNSA is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of KNSA (11.78) is better than 83.62% of its industry peers.
  • KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.78
ROIC/WACC0.88
WACC9.33%
KNSA Yearly LT Debt VS Equity VS FCFKNSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 3.79 indicates that KNSA has no problem at all paying its short term obligations.
  • KNSA has a Current ratio (3.79) which is in line with its industry peers.
  • A Quick Ratio of 3.39 indicates that KNSA has no problem at all paying its short term obligations.
  • KNSA has a Quick ratio of 3.39. This is comparable to the rest of the industry: KNSA outperforms 42.20% of its industry peers.
Industry RankSector Rank
Current Ratio 3.79
Quick Ratio 3.39
KNSA Yearly Current Assets VS Current LiabilitesKNSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. KNSA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 221.31% over the past year.
  • Measured over the past years, KNSA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -34.14% on average per year.
  • Looking at the last year, KNSA shows a very strong growth in Revenue. The Revenue has grown by 60.09%.
  • KNSA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 45.45% yearly.
EPS 1Y (TTM)221.31%
EPS 3Y-34.14%
EPS 5YN/A
EPS Q2Q%241.67%
Revenue 1Y (TTM)60.09%
Revenue growth 3Y45.45%
Revenue growth 5YN/A
Sales Q2Q%64.95%

3.2 Future

  • KNSA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.16% yearly.
  • KNSA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.42% yearly.
EPS Next Y105.97%
EPS Next 2Y76.67%
EPS Next 3Y48.01%
EPS Next 5Y45.16%
Revenue Next Year34.83%
Revenue Next 2Y25.34%
Revenue Next 3Y22.39%
Revenue Next 5Y17.42%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
KNSA Yearly Revenue VS EstimatesKNSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
KNSA Yearly EPS VS EstimatesKNSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

6

4. KNSA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 61.86, which means the current valuation is very expensive for KNSA.
  • Compared to the rest of the industry, the Price/Earnings ratio of KNSA indicates a rather cheap valuation: KNSA is cheaper than 89.21% of the companies listed in the same industry.
  • KNSA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.70.
  • KNSA is valuated quite expensively with a Price/Forward Earnings ratio of 30.04.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of KNSA indicates a rather cheap valuation: KNSA is cheaper than 92.49% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.84. KNSA is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 61.86
Fwd PE 30.04
KNSA Price Earnings VS Forward Price EarningsKNSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, KNSA is valued cheaper than 91.33% of the companies in the same industry.
  • KNSA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. KNSA is cheaper than 94.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF 25.69
EV/EBITDA 36.35
KNSA Per share dataKNSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • KNSA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of KNSA may justify a higher PE ratio.
  • A more expensive valuation may be justified as KNSA's earnings are expected to grow with 48.01% in the coming years.
PEG (NY)0.58
PEG (5Y)N/A
EPS Next 2Y76.67%
EPS Next 3Y48.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KNSA Dividend Analysis

5.1 Amount

  • No dividends for KNSA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KNSA Fundamentals: All Metrics, Ratios and Statistics

KINIKSA PHARMACEUTICALS INTE

NASDAQ:KNSA (3/13/2026, 8:00:02 PM)

After market: 45.78 0 (0%)

45.78

-0.29 (-0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)04-21
Inst Owners95.47%
Inst Owner Change-57.51%
Ins Owners3.24%
Ins Owner Change-21.79%
Market Cap3.50B
Revenue(TTM)677.56M
Net Income(TTM)59.01M
Analysts85.71
Price Target56.99 (24.49%)
Short Float %7%
Short Ratio5.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-42.87%
Min EPS beat(2)-55.48%
Max EPS beat(2)-30.25%
EPS beat(4)2
Avg EPS beat(4)23.7%
Min EPS beat(4)-55.48%
Max EPS beat(4)156.77%
EPS beat(8)3
Avg EPS beat(8)-795.94%
EPS beat(12)6
Avg EPS beat(12)-483.47%
EPS beat(16)10
Avg EPS beat(16)-333.06%
Revenue beat(2)2
Avg Revenue beat(2)3.78%
Min Revenue beat(2)1.62%
Max Revenue beat(2)5.94%
Revenue beat(4)4
Avg Revenue beat(4)4.02%
Min Revenue beat(4)1.62%
Max Revenue beat(4)5.94%
Revenue beat(8)5
Avg Revenue beat(8)2.71%
Revenue beat(12)9
Avg Revenue beat(12)6.1%
Revenue beat(16)12
Avg Revenue beat(16)8.92%
PT rev (1m)1.59%
PT rev (3m)3.47%
EPS NQ rev (1m)-7.44%
EPS NQ rev (3m)-8.83%
EPS NY rev (1m)-4.45%
EPS NY rev (3m)-11.42%
Revenue NQ rev (1m)2.59%
Revenue NQ rev (3m)1.94%
Revenue NY rev (1m)1.17%
Revenue NY rev (3m)4.02%
Valuation
Industry RankSector Rank
PE 61.86
Fwd PE 30.04
P/S 5.17
P/FCF 25.69
P/OCF 25.39
P/B 6.17
P/tB 6.34
EV/EBITDA 36.35
EPS(TTM)0.74
EY1.62%
EPS(NY)1.52
Fwd EY3.33%
FCF(TTM)1.78
FCFY3.89%
OCF(TTM)1.8
OCFY3.94%
SpS8.85
BVpS7.42
TBVpS7.22
PEG (NY)0.58
PEG (5Y)N/A
Graham Number11.11
Profitability
Industry RankSector Rank
ROA 7.73%
ROE 10.4%
ROCE 12.37%
ROIC 8.21%
ROICexc 24.37%
ROICexgc 26.28%
OM 11.4%
PM (TTM) 8.71%
GM 88.54%
FCFM 20.13%
ROA(3y)0.99%
ROA(5y)-5%
ROE(3y)1.25%
ROE(5y)-7.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y102.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y102.78%
ROICexc growth 5YN/A
OM growth 3Y36.93%
OM growth 5YN/A
PM growth 3Y-52.89%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5YN/A
F-Score8
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 100.9%
Cap/Sales 0.23%
Interest Coverage 250
Cash Conversion 175.16%
Profit Quality 231.2%
Current Ratio 3.79
Quick Ratio 3.39
Altman-Z 11.78
F-Score8
WACC9.33%
ROIC/WACC0.88
Cap/Depr(3y)40.93%
Cap/Depr(5y)198.53%
Cap/Sales(3y)0.11%
Cap/Sales(5y)10.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)221.31%
EPS 3Y-34.14%
EPS 5YN/A
EPS Q2Q%241.67%
EPS Next Y105.97%
EPS Next 2Y76.67%
EPS Next 3Y48.01%
EPS Next 5Y45.16%
Revenue 1Y (TTM)60.09%
Revenue growth 3Y45.45%
Revenue growth 5YN/A
Sales Q2Q%64.95%
Revenue Next Year34.83%
Revenue Next 2Y25.34%
Revenue Next 3Y22.39%
Revenue Next 5Y17.42%
EBIT growth 1Y269.29%
EBIT growth 3Y99.18%
EBIT growth 5YN/A
EBIT Next Year113.76%
EBIT Next 3Y67.22%
EBIT Next 5YN/A
FCF growth 1Y436.82%
FCF growth 3Y188.18%
FCF growth 5YN/A
OCF growth 1Y437.14%
OCF growth 3Y187.44%
OCF growth 5YN/A

KINIKSA PHARMACEUTICALS INTE / KNSA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for KINIKSA PHARMACEUTICALS INTE?

ChartMill assigns a fundamental rating of 7 / 10 to KNSA.


Can you provide the valuation status for KINIKSA PHARMACEUTICALS INTE?

ChartMill assigns a valuation rating of 6 / 10 to KINIKSA PHARMACEUTICALS INTE (KNSA). This can be considered as Fairly Valued.


Can you provide the profitability details for KINIKSA PHARMACEUTICALS INTE?

KINIKSA PHARMACEUTICALS INTE (KNSA) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for KNSA stock?

The Price/Earnings (PE) ratio for KINIKSA PHARMACEUTICALS INTE (KNSA) is 61.86 and the Price/Book (PB) ratio is 6.17.


How financially healthy is KINIKSA PHARMACEUTICALS INTE?

The financial health rating of KINIKSA PHARMACEUTICALS INTE (KNSA) is 7 / 10.